Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: Mura confers clinical resistance at low fitness cost

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2767-2769

  Couce, Alejandro ^a   Briales, Alejandra ^b   Rodríguez Rojas, Alexandro ^a   Costas, Coloma ^a   Pascual, Álvaro ^b   Blázquez, Jesús ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; FOSFOMYCIN; PROTEIN MURA; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL GENOME; ESCHERICHIA COLI; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; MURA GENE; NONHUMAN; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL;

ALKYL AND ARYL TRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC FITNESS; GENOME, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84860212663     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06122-11     Document Type: Article

References (24)

1. Alós JI, Garcia-Pena P, Tamayo J. 2007. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev. Esp. Quimioter. 20:211-215. (Pubitemid 47326190)
2. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489-493. (Pubitemid 29477174)
3. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard - 7th edition. CLSI M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Cordaro JC, et al. 1976. Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J. Bacteriol. 128:785-793.
5. Corvec S, et al. 2003. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemother. 52:629-635. (Pubitemid 37258424)
6. Depardieu F, Courvalin P, Kolb A. 2005. Binding sites of VanRB and sigma70 RNA polymerase in the vanB vancomycin resistance operon of Enterococcus faecium BM4524. Mol. Microbiol. 57:550-564. (Pubitemid 40979352)
7. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46:1069-1077. (Pubitemid 351589875)
8. Gismondo MR, et al. 1994. Escherichia coli: effect of fosfomycin trometamol on some urovirulence factors. J. Chemother. 6:167-172. (Pubitemid 24256124)
9. Horii T, Kimura T, Sato K, Shibayama K, Ohta M. 1999. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob. Agents Chemother. 43:789-793. (Pubitemid 29165741)
10. Kadner RJ, Winkler HH. 1973. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J. Bacteriol. 113:895-900.
11. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci. 235:364-386.
12. Kitagawa M, et al. 2005. Complete set of ORF clones of Escherichia coli ASKA library (a complete set of E. coli K-12 ORF archive): unique resources for biological research. DNA Res. 12:291-299.
13. Klein U, Pawelzik M, Opferkuch W. 1985. Influence of beta-lactam antibiotics, fosfomycin and vancomycin on the adherence (hemagglutination) of Escherichia coli-containing different adhesins. Chemotherapy 31: 138-145. (Pubitemid 15143706)
14. Maki H, Murakami K. 1997. Formation of potent hybrid promoters of the mutant llm gene by IS256 transposition in methicillin-resistant Staphylococcus aureus. J. Bacteriol. 179:6944-6948. (Pubitemid 27492476)
15. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22(Suppl. 2):53-59.
16. Marquardt JL, Siegele DA, Kolter R, Walsh CT. 1992. Cloning and sequencing of Escherichia coli murZ and purification of its product, a UDP-N-acetylglucosamine enolpyruvyl transferase. J. Bacteriol. 174: 5748-5752.
17. McAleese FM, Foster TJ. 2003. Analysis of mutations in the Staphylococcus aureus clfB promoter leading to increased expression. Microbiology 149:99-109. (Pubitemid 36175681)
18. Mendoza C, et al. 1980. Plasmid-determined resistance to fosfomycin in Serratia marcescens. Antimicrob. Agents Chemother. 18:215-219. (Pubitemid 11231235)
19. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858. (Pubitemid 37040258)
20. Oteo J, et al. 2010. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J. Antimicrob. Chemother. 65:2459-2463.
21. Poole K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56:20-51. (Pubitemid 41418335)
22. Soo VW, Hanson-Manful P, Patrick WM. 2011. Artificial gene amplification reveals an abundance of promiscuous resistance determinants in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 108:1484-1489.
23. Takahata S, et al. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 35:333-337.
24. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. 2010. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob. Agents Chemother. 54: 3061-3064.